Shanghai, China - April 10, 2020, Qiyu Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as QureBio) recently announced the completion of tens of millions of a + rounds of financing, invested by Shenzhen Venture Capital Health Industry Fund.
It is reported that this round of financing will be mainly used to promote the pre-clinical development of q-1802 and q-1801 projects. Founded in July 2017, the company is a R & D company focusing on innovative macromolecular biological drugs. The company aims to solve the intractable cancer, autoimmune diseases, metabolic diseases (such as diabetes, hyperlipidemia, etc.) and other difficult diseases, and actively develop therapeutic biological new drugs.